96
Participants
Start Date
June 18, 2021
Primary Completion Date
November 1, 2023
Study Completion Date
November 29, 2023
Hepalatide 2.1mg
2.1 mg/day subcutaneously (s.c.) for 24 week
Hepalatide 4.2mg
4.2mg/day subcutaneously (s.c.) for 24 week
Hepalatide 6.3mg
6.3mg/day subcutaneously (s.c.) for 24 week
placebo 2.1mg
2.1 mg/day subcutaneously (s.c.) for 24 week
placebo 4.2mg
4.2 mg/day subcutaneously (s.c.) for 24 week
placebo 6.3mg
6.3 mg/day subcutaneously (s.c.) for 24 week
Pegylated Interferon
180 ug/week subcutaneously (s.c.) for 28 week
The fifth medical center of PLA, Beijing
Jilin Hepatobiliary Disease Hospital, Changchun
The first hospital of Jilin University, Changchun
Chizhou People's Hospital, Chizhou
The First Hospital Affiliated to the Army Medical University, Chongqing
The First Affiliated Hospital of Nanchang University, Nanchang
The Second Hospital of Nanjing, Nanjing
Qingyuan People's Hospital, Qingyuan
Shanghai Tongren Hospital, Shanghai
The Sixth People's Hospital of Shenyang, Shenyang
Henan Provincial People's Hospital, Zhengzhou
Henan Provincial Infectious Disease Hospital, Zhenzhou
Shanghai HEP Pharmaceutical Co., Ltd.
INDUSTRY